NO20060502L - Forbindelser for behandling av metabolske forstyrrelser - Google Patents
Forbindelser for behandling av metabolske forstyrrelserInfo
- Publication number
- NO20060502L NO20060502L NO20060502A NO20060502A NO20060502L NO 20060502 L NO20060502 L NO 20060502L NO 20060502 A NO20060502 A NO 20060502A NO 20060502 A NO20060502 A NO 20060502A NO 20060502 L NO20060502 L NO 20060502L
- Authority
- NO
- Norway
- Prior art keywords
- carbon atoms
- hydrogen
- alkyl
- ring
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 perfluoromethoxy Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49653303P | 2003-08-20 | 2003-08-20 | |
| PCT/US2004/026561 WO2005018628A1 (en) | 2003-08-20 | 2004-08-16 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060502L true NO20060502L (no) | 2006-05-03 |
Family
ID=34216015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060502A NO20060502L (no) | 2003-08-20 | 2006-01-31 | Forbindelser for behandling av metabolske forstyrrelser |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7906675B2 (de) |
| EP (1) | EP1656127B1 (de) |
| JP (1) | JP4703563B2 (de) |
| KR (1) | KR101069276B1 (de) |
| CN (2) | CN1835743A (de) |
| AT (1) | ATE502631T1 (de) |
| AU (1) | AU2004266673B2 (de) |
| BR (1) | BRPI0413758A (de) |
| CA (1) | CA2533890A1 (de) |
| DE (1) | DE602004031954D1 (de) |
| IL (1) | IL173377A (de) |
| MX (1) | MXPA06001963A (de) |
| NO (1) | NO20060502L (de) |
| NZ (1) | NZ545268A (de) |
| RU (1) | RU2349584C2 (de) |
| UA (1) | UA88772C2 (de) |
| WO (1) | WO2005018628A1 (de) |
| ZA (1) | ZA200600577B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2530235T3 (es) * | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| KR101127390B1 (ko) * | 2003-04-15 | 2012-03-23 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| WO2004098496A2 (en) * | 2003-04-30 | 2004-11-18 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2006127133A2 (en) * | 2005-04-01 | 2006-11-30 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| KR20080086523A (ko) * | 2006-01-25 | 2008-09-25 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
| WO2007087505A2 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CN101374414A (zh) * | 2006-01-25 | 2009-02-25 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CN101378740A (zh) * | 2006-02-02 | 2009-03-04 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CA2637884A1 (en) * | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20100227901A1 (en) * | 2006-02-28 | 2010-09-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| MX2008012506A (es) * | 2006-03-31 | 2008-10-14 | Wellstat Therapeutics Corp | Tratamiento de combinacion de trastornos metabolicos. |
| KR20090010035A (ko) * | 2006-05-18 | 2009-01-28 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
| JP5252585B2 (ja) * | 2006-06-09 | 2013-07-31 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| JP5496913B2 (ja) * | 2008-01-15 | 2014-05-21 | ウェルスタット セラピューティクス コーポレイション | 代謝異常の治療のための化合物 |
| CN109096350B (zh) * | 2017-09-21 | 2020-07-28 | 暨南大学 | 辣木籽中新的硫醚类化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5035M (de) | 1964-07-28 | 1967-05-02 | ||
| DK1017379T3 (en) * | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
| KR100965201B1 (ko) | 2001-06-12 | 2010-06-24 | 웰스테트 테라퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| AU2003286728A1 (en) | 2002-11-01 | 2004-06-07 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2530235T3 (es) | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| KR101127390B1 (ko) | 2003-04-15 | 2012-03-23 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| EP1618086B1 (de) | 2003-04-22 | 2009-12-02 | Wellstat Therapeutics Corporation | Verbindungen zur behandlung von stoffwechselstörungen |
| WO2004098496A2 (en) | 2003-04-30 | 2004-11-18 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2004
- 2004-08-16 NZ NZ545268A patent/NZ545268A/en unknown
- 2004-08-16 UA UAA200602860A patent/UA88772C2/ru unknown
- 2004-08-16 US US10/566,302 patent/US7906675B2/en active Active
- 2004-08-16 CN CNA2004800235529A patent/CN1835743A/zh active Pending
- 2004-08-16 MX MXPA06001963A patent/MXPA06001963A/es active IP Right Grant
- 2004-08-16 DE DE602004031954T patent/DE602004031954D1/de not_active Expired - Lifetime
- 2004-08-16 AU AU2004266673A patent/AU2004266673B2/en not_active Ceased
- 2004-08-16 CA CA002533890A patent/CA2533890A1/en not_active Abandoned
- 2004-08-16 BR BRPI0413758-2A patent/BRPI0413758A/pt not_active IP Right Cessation
- 2004-08-16 AT AT04781277T patent/ATE502631T1/de not_active IP Right Cessation
- 2004-08-16 JP JP2006523964A patent/JP4703563B2/ja not_active Expired - Fee Related
- 2004-08-16 RU RU2006108572/04A patent/RU2349584C2/ru not_active IP Right Cessation
- 2004-08-16 CN CN2010102937097A patent/CN101948416A/zh active Pending
- 2004-08-16 EP EP04781277A patent/EP1656127B1/de not_active Expired - Lifetime
- 2004-08-16 KR KR1020067003221A patent/KR101069276B1/ko not_active Expired - Fee Related
- 2004-08-16 WO PCT/US2004/026561 patent/WO2005018628A1/en not_active Ceased
-
2006
- 2006-01-23 ZA ZA200600577A patent/ZA200600577B/en unknown
- 2006-01-26 IL IL173377A patent/IL173377A/en not_active IP Right Cessation
- 2006-01-31 NO NO20060502A patent/NO20060502L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070282003A1 (en) | 2007-12-06 |
| KR101069276B1 (ko) | 2011-10-04 |
| BRPI0413758A (pt) | 2006-10-31 |
| EP1656127A4 (de) | 2009-04-29 |
| NZ545268A (en) | 2009-05-31 |
| ATE502631T1 (de) | 2011-04-15 |
| IL173377A (en) | 2012-12-31 |
| WO2005018628A1 (en) | 2005-03-03 |
| RU2349584C2 (ru) | 2009-03-20 |
| RU2006108572A (ru) | 2006-07-27 |
| ZA200600577B (en) | 2007-01-31 |
| JP4703563B2 (ja) | 2011-06-15 |
| CN101948416A (zh) | 2011-01-19 |
| AU2004266673B2 (en) | 2010-08-05 |
| EP1656127B1 (de) | 2011-03-23 |
| MXPA06001963A (es) | 2006-05-31 |
| CA2533890A1 (en) | 2005-03-03 |
| UA88772C2 (ru) | 2009-11-25 |
| CN1835743A (zh) | 2006-09-20 |
| HK1087040A1 (en) | 2006-10-06 |
| DE602004031954D1 (de) | 2011-05-05 |
| IL173377A0 (en) | 2006-06-11 |
| EP1656127A1 (de) | 2006-05-17 |
| AU2004266673A1 (en) | 2005-03-03 |
| JP2007502824A (ja) | 2007-02-15 |
| US7906675B2 (en) | 2011-03-15 |
| KR20060066730A (ko) | 2006-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081821L (no) | Forbindelser for behandling av metabolske forstyrrelser | |
| NO20053211L (no) | Forbindelser for behandling av metabolske forstyrrelser. | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007095462A3 (en) | Compounds for the treatment of metabolic disorders | |
| MXPA05011592A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| NO20003399L (no) | <Alfa>-amionoamidderivater som er nyttige som smertestillende midler | |
| KR960010000A (ko) | 종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물 | |
| WO2004093806A3 (en) | Compounds for the treatment of metabolic disorders | |
| PH12015501098A1 (en) | Antituberculous composition comprising oxazole compounds | |
| UA88772C2 (ru) | Соединения для лечения расстройств метаболизма | |
| WO2008142986A1 (ja) | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する含窒素複素環誘導体 | |
| NO20063330L (no) | Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer | |
| EP1868595A4 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007087504A3 (en) | Compounds for the treatment of metabolic disorders | |
| NO20074738L (no) | Aktivator for peroksisom-proliferator som aktiverer reseptor delta | |
| WO2006092507A8 (fr) | Derives de 1 ,2,4-triazines, leur preparation et leur application en therapeutique humaine | |
| WO2007092729A3 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |